Kinetic modeling of the interactions between 4-Methylumbelliferone, 1-Naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites
dc.contributor.author | Galetin, A | |
dc.contributor.author | Mackenzie, Peter Ian | |
dc.contributor.author | Williams, Andrew | |
dc.contributor.author | Miners, John Oliver | |
dc.contributor.author | Uchaipichat, Verawan Nu | |
dc.contributor.author | Houston, J Brian | |
dc.date.accessioned | 2010-07-27T06:23:03Z | |
dc.date.available | 2010-07-27T06:23:03Z | |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | Uchaipichat, V.N., Galetin, A., Houston, J., Mackenzie, P.I., Williams, A., & Miners, J.O., 2008. Kinetic modeling of the interactions between 4-Methylumbelliferone, 1-Naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Molecular Pharmacology, 74(4), 1152-1162. | en |
dc.identifier.issn | 0026-895X | en_US |
dc.identifier.uri | http://hdl.handle.net/2328/11434 | |
dc.title | Kinetic modeling of the interactions between 4-Methylumbelliferone, 1-Naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites | en_US |
dc.type | Article | en_US |
dc.identifier.rmid | 2006009376 | en_US |
dc.identifier.doi | https://doi.org/10.1124/mol.108.048645 | en |
dc.subject.forgroup | 1115 Pharmacology and Pharmaceutical Sciences | en_US |
local.contributor.authorOrcidLookup | Mackenzie, Peter Ian: https://orcid.org/0000-0002-0697-6878 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
1115 - Pharmacology and Pharmaceutical Sciences
Flinders' staff research in Pharmacology and Pharmaceutical Sciences, reportable as part of ERA, 2001- -
1115 - Pharmacology and Pharmaceutical Sciences
Flinders' research in Pharmacology and Pharmaceutical Sciences, as reported for ERA 2012.